Sign in
Taking people in NetherlandsPhase 4

Methotrexate levels in red blood cells of young people with Crohn's disease

Measures methotrexate levels over time in children and teenagers with Crohn's disease.

Key facts

Who runs it
Amsterdam UMC Stichting
Where
Amsterdam, Enschede, Groningen, and Utrecht, NetherlandsSee the 4 sites
Registry title
Methotrexate in paediatric and adolescent Crohn’s disease: an observational study
Status
Recruiting
Phase
Phase 4
People taking part
215 people, planned
Started
15 Jul 2026
Expected to end
1 Feb 2030
Type of study
Interventional
Record updated
30 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children, teenagers and young adults with Crohn's disease who are about to start methotrexate (MTX), alone or together with infliximab.

Age
4-28 years
Sex
Women and men can join.
Disease stage
Crohn's disease proven by endoscopic, radiological and histologic findings.
Earlier treatment
Must be about to start MTX treatment, either alone or together with infliximab. Cannot be treated with a biologic agent other than infliximab.

Main reasons for not taking part

  • Not able to receive MTX, as in usual care
  • Treatment with a biologic agent other than infliximab
  • Cannot read and understand the patient and family information sheets
  • Informed consent of the patient not obtained when required

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Age of 4-28 years
  • Written informed consent of patient (if indicated) and parents (if indicated) has been obtained
  • Proven diagnosis of Crohn’s disease based on endoscopic, radiological and histologic findings
  • Will start MTX treatment monotherapy or combination therapy with infliximab

Who cannot take part

  • Co-treatment with a biologic agent other than infliximab
  • Not eligible to receive MTX, as in usual care
  • Inability to read and understand the patient and family information sheets
  • Informed consent of patient has not been obtained when required

Where in Netherlands

  • Amsterdam UMC StichtingAmsterdam, NetherlandsTaking people
  • Medisch Spectrum TwenteEnschede, NetherlandsTaking people
  • Universitair Medisch Centrum GroningenGroningen, NetherlandsTaking people
  • Universitair Medisch Centrum UtrechtUtrecht, NetherlandsTaking people

About the trial

What the trial wants to find out

[PK] Determination of MTX-PG concentrations and identification of accumulation patterns over time in RBCs. [PD] Association of MTX-PG concentration with MTX discontinuation due to a lack of efficacy or toxicity.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Methotrexate in paediatric and adolescent Crohn’s disease: an observational study
Plain-language title
Methotrexate levels in red blood cells of young people with Crohn's diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
30 July 2026